Sign in or register to see full information and data.

Studies / CAVD 521


Study information

Grant Affiliation:Farzan: Preventing HIV-1 transmission with a novel entry inhibitor, eCD4-Ig
Strategy:Prophylactic neutralizing Ab
Study Type:Antibody Screening
Species:Non-Organism Study
Stage:Assays Completed
Study Start Date:2015-09-30
Study Made Public:2016-12-16


Neutralization of eCD4-Ig variants 1v34 and 2v26


CAVD 521 is a monoclonal antibody screening study evaluating the neutralization of IC50s and IC80s using a panel of 200 Clade C isolates (Early/Acute Pseudovirus Panel) for two eCD4-Ig variants.


No Products used in study

Integrated data

No integrated data is available for this study.

Non-integrated data

No non-integrated data is available for this study.